Ophthalmology Times Newsletter

To view this email as a web page, click here.

AAO 2019 Retina Street Team: Day 3

AAO 2019 Retina Street Team: Gang of 4

Judy E. Kim, MD; David M. Brown, MD; and Charlie C. Wykoff, MD,PhD, share their take on key highlights — what’s in the pharmaceutical pipelines, upcoming and ongoing clinical trials, and the latest update in gene therapy — from this year’s annual meeting of the American Academy of Ophthalmology.

Watch the video

Encouraging results revealed from early trial of subretinal gene therapy for wet AMD

Key takeaways from the RGX-314 (Regenxbio) phase I/IIa clinical trial indicate that the novel gene therapy is a promising approach for treating wet age-related macular degeneration (AMD).

Learn more

AAO 2019 Retina Street Team: J. Fernando Arevalo, MD, FACS

J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether brolocuizumab is better than current treatment, at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco, California.

Watch here

AAO 2019 Retina Street Team: John T. Thompson, MD

Ophthalmologists alerted to recently described drug-induced maculopathy

AAO 2019 Retina Street Team: Allen C. Ho, MD

Gene therapy focus of Schepens lectures at AAO 2019

AAO 2019 Retina Street Team: Jennifer K. Sun, MD

Several cyst characteristics linked to ischemia in DME

What to expect at this year's AAO meeting

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.